Pinned Tweet
As football season kicks off, hospital and health system names will be displayed prominently on stadiums and arenas across the country. But while those names are visible, how hospitals spend revenues generated through the 340B program often isn't.
It's time for Congress to reform 340B and ensure the program benefits the patients it was created to serve.
Learn more: ow.ly/fe3u50ZLuyW
With just weeks until Election Day, voters have already sent a clear message: Voters prefer candidates focused on lowering health insurance costs and reducing barriers to care. Voters are sounding the alarm on the costs and barriers they face at the hands of health insurers and their middlemen. See the @votersforcures /@MorningConsult poll results: votersforcures.org/resources…
In just 15 days, voters will make their voices heard in the 2026 midterm elections – so what are their priorities when it comes to health care?
Well, health insurance costs like deductibles, copays and premiums rank highest in voters' health care priorities.
Hear more from a recent @votersforcures poll: ow.ly/jyVx50ZZ1Xn
Yesterday, our @PhRMA team made 1,057 sandwiches in just one hour—nearly 18 per minute—benefitting @MarthasTableorg. I’m always proud when our team dedicates their time and energy to help feed our neighbors.
A new report finds hospitals, clinics and their for-profit partners generated $142B in profits from 340B medicine markups in 2025 alone. The evidence is clear: The debate is no longer whether the federal 340B program needs reform, but how to reform it to ensure the program serves the patients it was created to help. Learn more: ow.ly/o8wQ50ZTs4p
After more than a decade at @PhRMA, I'm proud of what we've accomplished together on behalf of patients and innovation. I'm excited to pass the baton to Eric Cantor, whose leadership and experience will help guide the industry through a period of extraordinary scientific opportunity. I have personally known Eric for many years and am confident he will be a terrific leader for PhRMA.
phrma.org/resources/phrma-se…
China is investing aggressively in biopharmaceutical innovation, and the competitive landscape is changing.
The Administration's recent efforts to strengthen the U.S. clinical trial environment are an important step toward keeping investment, research and the next generation of medical breakthroughs here at home.
I appreciated the opportunity to discuss these challenges with @BrodyMullinsDC and @camoosomiller on the @decidersshow Podcast.
Good policy should strengthen competition, not weaken it.
Nearly 9 in 10 prescriptions filled in the U.S. are low-cost generics. As policymakers consider MFN, it's important to preserve the incentives that support generic competition and help keep medicines affordable.
Learn more: ow.ly/XMvp50ZOFTv
Since 1992, PDUFA has fostered an efficient, predictable and science-based regulatory ecosystem. As a result, more than 70% of new medicines are approved in America first. We encourage Congress to move swiftly to reauthorize PDUFA.
Learn more: ow.ly/Zf0O50ZNZmC
Making medicine easier for a patient to take matters. CMS is considering an approach that could discourage investment in new treatment advances designed to make care easier and more convenient for patients. We shouldn’t discourage that kind of innovation.
ow.ly/TNJx50ZNQUI
.@GileadSciences' new Research Center reflects their commitment to American innovation and medical breakthroughs. Thanks to biopharmaceutical investments like these, America is where medical breakthroughs happen. Read more: gilead.com/news/news-details…
Insurers are trying to flip the script on patients. 70% of insured patients were denied coverage for new medicines in 2024. It’s time for more accountability from the middlemen standing between patients and their medicines. Learn more: PhRMA.org/PBMs
America’s leadership in medical innovation is built on strong innovation ecosystems across the country, and Pennsylvania is an important part of that story.
Tune into @axios Live for a closer look at what’s driving that leadership.
WATCH: @BrockEWTurner, @MikeDonofrio_ and @IsaacAvilucea host conversations in Philadelphia on the innovation, investment and workforce driving Pennsylvania’s life sciences future with @UCScienceCenter interim president and CEO Kerry Benson, @PAChamber president and CEO @LukeBernstein and Pennsylvania state @RepBorowski. #AxiosLive
xitter.cf/i/broadcasts/1PKqrNzkb…
340B modernization is long overdue.
A rebate model will bring greater transparency and accountability to the program while strengthening it for patients and true safety-net providers.
An important step in the right direction.
Learn more: ow.ly/z6BC50ZKYy6
America's competitive advantage in biopharmaceutical innovation depends on a regulatory system that keeps pace with scientific progress. The Prescription Drug User Fee Act (PDUFA) has helped provide that foundation, and it remains critical to U.S. leadership.
Read more: ow.ly/fqou50ZHLSy
Innovation is more than discovering new medicines. The FDA's approval of the first at-home starting dose for an Alzheimer's treatment is an important step for patients and caregivers. America must continue to support the innovation ecosystem that delivers advancements like this.
ow.ly/KlWl50ZGFi0
The most meaningful part of this role has been meeting the researchers, scientists and patients behind today's medical breakthroughs.
Stories from patients whose lives have been changed by innovation are a powerful reminder of why this work matters.
Thanks to @BrodyMullinsDC and @camoosomiller Miller for the opportunity to discuss this on @decidersshow.
Developing a new medicine takes years of research and significant investment. The right policy framework supports innovation while creating a pathway for low-cost generics and biosimilars to become available. Getting that balance right benefits patients.
ow.ly/wl6C50ZCsve
America's leadership in biopharmaceutical innovation delivers more than medical breakthroughs. Newly announced investments by PhRMA member companies are expected to generate $1.2 trillion in economic activity and support 100,000+ jobs across the country. Policies that support innovation help keep that momentum going.
ow.ly/gnhA50ZC2gE
The progress we're seeing in medicine today is the result of years of scientific discovery. Multiple advances across areas like cancer treatment and gene editing therapies are helping define new possibilities for patients. Continued progress depends on supporting research and innovation.
ow.ly/HCLM50ZAWwz
Thanks to @BrodyMullinsDC and @camoosomiller for having me on @decidersshow to discuss why PBM reform matters.
For years, we've worked to help policymakers better understand the role PBMs play in the health care system. Recent action by Congress, the FTC and the Department of Labor reflects growing momentum for reforms that increase transparency and help lower costs for patients.